HealthCare Global Enterprises Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

HealthCare Global Enterprises wird ein jährliches Gewinn- und Umsatzwachstum von 62.5% bzw. 12.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 64.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.7% betragen.

Wichtige Informationen

46.8%

Wachstumsrate der Gewinne

46.8%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	25.6%
Wachstumsrate der Einnahmen	11.8%
Zukünftige Eigenkapitalrendite	11.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	31 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

Recent updates

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

Sep 14

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

Sep 05

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

May 17

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Jun 24

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Jun 03

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Dec 08

What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?

Jun 25

Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares

Mar 14

The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On

Mar 03

Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt

Jan 27

How Many HealthCare Global Enterprises Limited (NSE:HCG) Shares Did Insiders Buy, In The Last Year?

Dec 23

Reflecting on HealthCare Global Enterprises' (NSE:HCG) Share Price Returns Over The Last Three Years

Nov 10

What Type Of Shareholders Own The Most Number of HealthCare Global Enterprises Limited (NSE:HCG) Shares?

Sep 18

Gewinn- und Umsatzwachstumsprognosen

NSEI:HCG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	28,421	2,618	N/A	N/A	1
3/31/2026	24,270	1,388	2,254	N/A	9
3/31/2025	21,788	842	2,015	N/A	8
3/31/2024	19,193	398	915	N/A	9
12/31/2023	18,592	353	N/A	N/A	N/A
9/30/2023	18,140	371	922	2,197	N/A
6/30/2023	17,471	309	N/A	N/A	N/A
3/31/2023	16,944	293	1,184	2,516	N/A
12/31/2022	16,174	270	N/A	N/A	N/A
9/30/2022	15,507	-264	1,156	2,364	N/A
6/30/2022	14,827	694	N/A	N/A	N/A
3/31/2022	13,978	537	1,489	2,201	N/A
12/31/2021	13,312	-544	N/A	N/A	N/A
9/30/2021	12,472	-379	1,089	1,510	N/A
6/30/2021	11,431	-1,633	N/A	N/A	N/A
3/31/2021	10,134	-1,935	851	1,205	N/A
12/31/2020	9,858	-1,349	N/A	N/A	N/A
9/30/2020	9,897	-1,284	751	1,271	N/A
6/30/2020	10,202	-1,284	N/A	N/A	N/A
3/31/2020	10,956	-1,067	223	1,301	N/A
12/31/2019	10,832	-718	N/A	N/A	N/A
9/30/2019	10,541	-552	N/A	N/A	N/A
6/30/2019	10,210	-394	N/A	N/A	N/A
3/31/2019	9,787	-248	-903	985	N/A
12/31/2018	9,430	-135	N/A	N/A	N/A
9/30/2018	9,004	-41	N/A	N/A	N/A
6/30/2018	8,661	124	N/A	N/A	N/A
3/31/2018	8,307	205	-1,583	978	N/A
12/31/2017	7,909	257	N/A	N/A	N/A
9/30/2017	7,608	278	N/A	N/A	N/A
6/30/2017	7,237	219	N/A	N/A	N/A
3/31/2017	7,001	230	N/A	913	N/A
12/31/2016	6,705	208	N/A	N/A	N/A
9/30/2016	6,392	133	N/A	N/A	N/A
6/30/2016	6,081	67	N/A	N/A	N/A
3/31/2016	5,842	-178	N/A	732	N/A
12/31/2015	5,611	-33	N/A	N/A	N/A
9/30/2015	5,494	9	N/A	763	N/A
6/30/2015	5,323	9	N/A	N/A	N/A
3/31/2015	5,194	8	N/A	597	N/A
3/31/2014	4,513	-356	N/A	514	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HCGDas prognostizierte Gewinnwachstum (62.5% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: HCGDie Erträge des Unternehmens (62.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: HCGEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: HCGDie Einnahmen des Unternehmens (12.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: HCGDie Einnahmen des Unternehmens (12.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HCGDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.7 %).

HealthCare Global Enterprises Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 16%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 11%

Price target decreased to ₹350

Price target increased to ₹377

Recent updates

HealthCare Global Enterprises Limited to Report Q4, 2024 Results on May 29, 2024

Temasek May Bid for CVC's 60% Stake in Healthcare Global

EQT, TPG and KKR Reportedly Eye Majority Stake in HCG

New major risk - Financial position

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2024 Results on Feb 08, 2024

Consensus EPS estimates fall by 16%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q2, 2024 Results on Nov 09, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Radiation Business from Amrish Oncology Services Private Limited.

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Oncology Business from SRJ Health Care Private Limited.

CVC Capital Mulls Selling Stake in HealthCare Global Enterprises

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 20, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders.

HealthCare Global Enterprises Limited Announces CFO Changes

Consensus EPS estimates increase by 12%

New major risk - Financial position

HealthCare Global Enterprises Limited (NSEI:HCG) executed business transfer agreement to acquire Radiation Business from Amrish Oncology Services Private Limited for INR 160 million.

First quarter 2024 earnings: EPS misses analyst expectations

HealthCare Global Enterprises Limited to Report Q1, 2024 Results on Aug 10, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) entered into a share purchase agreement to acquire Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders for approximately INR 140 million.

Executive Chairman recently sold ₹1.1b worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

HealthCare Global Enterprises Limited to Report Q4, 2023 Results on May 25, 2023

Insider recently sold ₹794k worth of stock

Insider recently sold ₹1.7m worth of stock

Insider recently sold ₹2.9m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2023 Results on Feb 09, 2023

Insider recently sold ₹846k worth of stock

Insider recently sold ₹332k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹0.53 (vs ₹8.22 in 2Q 2022)

HealthCare Global Enterprises Limited to Report Q2, 2023 Results on Nov 10, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

Price target decreased to ₹350

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q1, 2023 Results on Aug 10, 2022

Executive Chairman recently sold ₹500m worth of stock

HealthCare Global Enterprises Limited (BSE:539787) agreed to acquire Radiation therapy centre of Radiant Hospital Services Private Limited from Radiant Hospitality Services Private Limited for INR 160 million.

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Now 21% undervalued

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Price target increased to ₹377

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to ₹293

HealthCare Global Enterprises Limited to Report Fiscal Year 2022 Results on May 26, 2022

High number of new and inexperienced directors

Insider recently sold ₹719k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Healthcare Global Enterprises Limited Announces Board Appointments

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Non-Executive Independent Director Shanker Annaswamy has left the company

Price target increased to ₹266

Second quarter 2022 earnings released: EPS ₹8.22 (vs ₹1.94 loss in 2Q 2021)

Insider recently sold ₹1.2m worth of stock

HealthCare Global Enterprises Limited (BSE:539787) agreed to acquire Hospital Lab Management and Clinical Research Site Management units of Strand Life Sciences.

First quarter 2022 earnings released: ₹0.76 loss per share (vs ₹4.48 loss in 1Q 2021)

High number of new directors

What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?

Price target increased to ₹196

Full year 2021 earnings released: ₹17.02 loss per share (vs ₹12.05 loss in FY 2020)

Non-Executive Independent Director Bhushani Kumar has left the company